The DNlite Test

Diabetic Kidney Disease (DKD) is Huge Healthcare Burden
 

50% of T2DM have some level of kidney disease.

There is high risk to become progressive decline of kidney function loss.

End stage kidney disease or kidney failure requires treatment by dialysis or kidney transplant.

DKD progression makes healthcare management complicated and costly.



Unmet Need:

A new DKD biomarker as better predictor to identify patients who will progress
 

Current diagnosis of Diabetic Kidney Disease (DKD) relies on test of Urine Albuminuria-to-Creatinine Ratio (UACR) and estimation of GFR (eGFR), but they cannot meet the required sensitivity and specificity. Furthermore, both UACR and eGFR cannot predict and identify DKD patients who will progress, which is crucial for DKD management.


Current Standard Unable to Predict Kidney Progression

 

UACR
  • Many patients with Micro-Albuminuria revert to Normal Albuminuria
 
  • Patients may also progress to kidney failure from Normal or Micro-Albuminuria

 
eGFR
  • Disease can progress years without apparent symptoms (progressive eGFR decline)
 

 

  


Our Solution: The DNlite Test

 

DNlite test is a series of patented and clinically validated non-invasive urine test for DKD Management. Patients in early stage of diabetes or with DKD are strongly recommended to manage the progression by DNlite test.



Currently, there are 2 types of DNlite tests: DNlite-IVD103 and DNlite-DN_Score.


 


DNlite: Best Solution in DKD Management

Early diagnostic insight enables early action for the right patients